NGS Banner

The SureSeq™ Myeloid Fusion Panel, crafted in collaboration with leading experts in myeloid cancer research to align seamlessly with the latest clinical guidelines, was used in this study. Harnessing RNA-based partner gene agnostic technology, our panel allows for simultaneous interrogation of multiple baited target fusions enhancing sample classification, including identification of novel and rare fusions.

 

Introduction

Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are both heterogeneous groups of hematological malignancies characterized by both phenotypic and genetic diversity, for which fusion genes are particularly prevalent1. For example in AML, well-documented fusion events include RUNX1::RUNX1T1, CBFB::MYH11 and PML::RARA, as well as rearrangements involving KMT2A and NUP982.

Please complete the form below to access the full app note

You might also be interested in

Assessment of Interpret software on low-frequency variants using reference standards

  • Resource type: Scientific poster
  • Application: Haematology, Solid tumour
Read

Understanding myeloid disorders with next-generation sequencing

  • Resource type: White paper
  • Application: Haematology
Read

Selecting the best NGS enrichment assay for your needs

  • Resource type: App note
  • Application: Haematology, Solid tumour, Cytogenetics & rare disease
Read
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter